Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lilly's move to hide Phase 1 pipeline draws mixed reviews

As its world-leading GLP-1 earns more than any other medicine — and its market cap eclipses all other healthcare companies — Eli Lilly has decided to stop disclosing its Phase 1 pipeline. Lilly

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 27 August →